Based in treatment options for other cancers, we identified some potential targetable genomic alterations such as PIK3CA and EGFR to help the selection of patients with PSCC for future clinical trials with targeted therapies including Alpelisib and Cetuximab. Here, PIK3CA is linked to cancer.